preclinical validation

The journey from scientific discovery to patient benefit is often long and uncertain. But in recent years, lipid nanoparticles (LNPs) have emerged as a key enabler for accelerating the clinical translation of innovative therapies, including mRNA, proteins, peptides, and gene-editing tools. At DIVERSA, we are designing next-generation nanoparticles that [...]